Moxifloxacin & Cefixime Sustained Release Tablets – Praiva CF Tablets

PRAIVA CF Tablets
Composition:- Moxifloxacin 400mg + Cefixime 400 mg.

PRAIVA CF Tablets – Moxifloxacin & Cefixime Sustained Release Tablets is a combination of Moxifloxacin, a 4th-generation fluoroquinolone, which exhibits enhanced activity against both typical and atypical respiratory pathogens and anaerobes. Cefixime complements with extended Gram-negative activity, offering synergistic coverage for resistant urinary, ENT, and LRTI infections. Once-daily dosing with excellent tissue penetration and post-antibiotic effect improves patient compliance and clinical outcomes in respiratory tract infections.

Key Points of Moxifloxacin & Cefixime Sustained Release Tablets – PRAIVA CF Tablets
• Enhanced Efficacy with Dual Bactericidal Coverage – A combination tablet provides synergistic benefits as Moxifloxacin helps manage respiratory pathogens with bactericidal activity, while Cefixime provides additional action against gram-negative bacteria.
• Broad Spectrum Coverage – Effective against a broad range of pathogens, gram-negative bacteria, and anaerobes.
• Versatile Infection Management – Addresses a wide range of infections such as respiratory tract infections, urinary tract infections, skin and soft tissue infections, and mixed bacterial infections.

Can be Prescribed by:
• Infectious Disease Specialists
• Pulmonologists
• Urologists
• Dermatologists
• General Physicians
• Healthcare practitioner

Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.